A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK

Código QR

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK

Philip Hykin,1 Usha Chakravarthy,2 Andrew Lotery,3 Martin McKibbin,4 Jackie Napier,5 Sobha Sivaprasad1,6 On behalf of the AURA Study Group 1National Institute for Health Research Biomedical Research Centre in Ophthalmology, Moorfields Eye Hospital, London, UK; 2Institute of Clinical Science, The Qu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hykin P, Chakravarthy U, Lotery A, McKibbin M, Napier J, Sivaprasad S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	neovascular or wet age-related macular degeneration treatment medical anti–vascular endothelial growth factor Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/fd84137aba1148d3ae55e7a656c76a1c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
por: Almeida DRP, et al.
Publicado: (2021)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa AC, et al.
Publicado: (2016)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam C, et al.
Publicado: (2015)

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
por: Chung WH, et al.
Publicado: (2016)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema MR, et al.
Publicado: (2021)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel PJ, et al.
Publicado: (2017)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen ER, et al.
Publicado: (2020)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020)

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
por: Sagong M, et al.
Publicado: (2021)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2017)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
por: Jing Wang, et al.
Publicado: (2021)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat D, et al.
Publicado: (2020)

Side Effects of Brolucizumab
por: Tahmineh Motevasseli, et al.
Publicado: (2021)

Quantitative Comparison of the Vascular Structure of Macular Neovascularizations Between Swept-Source and Spectral-Domain Optical Coherence Tomography Angiography
por: Faatz H, et al.
Publicado: (2020)

OCT Angiography-based Evaluation of the Choriocapillaris in Neovascular Age-related Macular Degeneration
por: Varsha Pramil, et al.
Publicado: (2021)

The Anti-Inflammatory Effect of Hydrogen Gas Inhalation and Its Influence on Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular Age-Related Macular Degeneration
por: I-Chia Liang, et al.
Publicado: (2021)

Comparison of choroidal neovascularization secondary to white dot syndromes and age-related macular degeneration by using optical coherence tomography angiography
por: Wang JC, et al.
Publicado: (2018)

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
por: Miyamoto N, et al.
Publicado: (2017)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
por: Ryu G, et al.
Publicado: (2021)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration
por: Wingard JB, et al.
Publicado: (2019)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma K, et al.
Publicado: (2018)

Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
por: Modjtahedi BS, et al.
Publicado: (2020)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou SA, et al.
Publicado: (2017)

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
por: Andrea Montesel, et al.
Publicado: (2021)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta H, et al.
Publicado: (2020)

To Peel or Not to Peel: Pars Plana Vitrectomy with Macular Membrane Peel in Eyes with Abnormalities of Vitreomacular Interface and Coexisting Dry Age-Related Macular Degeneration
por: Furashova O, et al.
Publicado: (2020)

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
por: Solomon SD, et al.
Publicado: (2021)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore RP, et al.
Publicado: (2017)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova NP, et al.
Publicado: (2016)

The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown
por: Ashrafzadeh S, et al.
Publicado: (2021)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Dimitrios A Karagiannis, et al.
Publicado: (2009)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong AH, et al.
Publicado: (2013)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Joseph Juliano, et al.
Publicado: (2021)